Get your patients on the right track

with Invitae's pharmacogenomic medication optimization tools

Your patients' health is your top priority.

If their drug therapies aren't helping, where can you turn?

Through Invitae's pharmacogenomic (PGx) medication optimization tools, you can achieve optimal prescribing by addressing barriers to precision medication management. With actionable, personalized drug and dose optimization recommendations based on a combination of genetics and the latest evidence presented directly in your clinical workflow or accessible securely through the web, you can easily design an effective regimen for each individual patient.

Pharmacogenomic-specific guidelines and published evidence affects hundreds of commonly used medications, including frequently prescribed medications for high-risk patients in cardiology, diabetes, pain management, psychiatry and oncology.

With pharmacogenomic testing, providers can:

Minimize side effects

Reduce ADEs and treatment failures

Improve patient care

Save time and reduce costs

About Invitae's clinical decision support tool

Invitae's clinical decision support tool offers one of the most comprehensive medication management analytics software on the market. Entirely evidence-based, the tool makes the complex process of customizing prescriptions to an individual's inherent drug metabolizing capacity easier. With pharmacists and physicians regularly updating the analytics and testing panel, you can be confident that all prescribing guidance is inline with current research. Invitae's clinical decision support tool puts the growing body of drug metabolism knowledge at your fingertips, enabling you to determine which prescription medications and doses are best for each patient.

www.invitae.com/pgx-tool

INVITAE

Right drug. Right dose. Right now.

PGx testing helps doctors determine the correct medication and dose based on each patient's metabolism, resulting in improved efficacy of medications and reduced risk of adverse effects. When it comes to your patients' health, the numbers speak for themselves:

Approximately

99%

of the population is **unable to process certain medications** in the way they are intended.[1]

Currently, over

200 drugs

have pharmacogenomic information in their product label from the **Food and Drug Administration**.[4]

When integrated into care, the tool decreases readmission and emergency department (ED) visit rates.[5]

52%
p=0.007
Readmissions

42%
g=0.045
ED

Cost-effective 25-gene panel

CYP2D6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, CYP1A2, CYP2B6, CYP4F2, ADRA2A, COMT, DPYD, F2, F5, GRIK4, HTR2A, HTR2C, HLA-B*57:01, IFNL3, MTHFR, NAT2, OPRM1, SLCO1B1, TPMT, UGT1A1, VKORC1

covers 80% of medications with high-evidence drug-gene impact

Personalized prescribing with Invitae's clinical decision support tool enables selection of the right drug and right dose for every patient.

Ready to get started?

To learn more about how pharmacogenomic testing can help your patients, contact us at clientservices@invitae.com or (800) 436-3037.

1. Ji Y *et al. J Mol Diagn.* 2016 May; 18(3): 438–445.
2. Centers for Disease Control and Prevention. Medication safety basics. September 2010.
3. Annals of Pharmacotherapy 2018, Vol. 52(9) 829–837
4. FDA. Table of pharmacogenomic biomarkers in drug labeling. Updated June 2018.
5. Elliott LS *et al. Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial. PLOS One.* 2017 12(2): e0170905.

HEADQUARTERS | 1400 16th Street, San Francisco, CA 94103 | ONLINE | www.invitae.com | CONTACT | www.invitae.com/contact